In a hearing prompted by a petition from the Indian Medical Association (IMA), the court accused Ramdev and Balkrishna of “deliberately ignoring” the court’s instructions that their product Coronil could treat COVID-19. The company was reprimanded for spreading misleading advertisements claiming that
Dr. Jaish Lele, former vice-president of IMA, praised the court’s stance and stressed that the order not only targeted Coronil but also emphasized accountability for all Patanjali medicines. He highlighted the humiliation faced by allopathic doctors and Patanjali’s false portrayal of allopathic medicine as inferior to Ayurveda.
“This order is not only against Coronil but also against all Patanjali medicines. Despite us registering an FIR in Patna, Madhya Pradesh and filing various complaints with the police, no action has been taken. was not raised, and they not only talked about Coronil, but “they continued to shame allopathic doctors and allopathic medicine, and continued to falsely claim that allopathic medicine is wrong and that Ayurveda is the best.” , we welcome the strong actions that the Supreme Court has initiated, taken and noted. So we are very grateful to the Supreme Court for the Court,” Lele said in an interview with CNBC-TV18. mentioned in.
The controversy surrounding Coronil dates back to its launch in early 2021, amid a surge in coronavirus cases in India. At a launch event attended by former health minister Harsh Vardhan and transport minister Nitin Gadkari, Ramdev touted the tablet as the “first evidence-based, researched treatment” for COVID-19.
Following subsequent scrutiny by the IMA, the government’s Ayush ministry refuted Ramdev’s claims by clarifying that Coronil was only approved as an “immune booster”. Despite this clarification, the controversy escalated further when the Haryana government announced plans to distribute 100,000 Coronil kits to coronavirus patients.
Amicus lead attorney Murali Neelakantan emphasized the legal framework surrounding these claims, saying, “The law is very clear… none of these drugs can find any basis in their books… None of these have proven their effectiveness.” ”
Further, Mr. Neelakantan pointed to the role of government support in promoting the sale of such products and suggested that without this support, such ventures would not be successful.
In today’s proceedings, the court also slammed the Uttarakhand regulator for not taking action against Patanjali. The court indicated it intended to issue a notice of contempt to state regulators, but refrained from issuing one immediately. The matter was adjourned until April 16.
(Editor: Jomy Jos Purkaran)
